Search

Fusing multi-modality data is crucial for accurate identification of brain disorder as different modalities can provide complementary perspectives of complex neurodegenerative disease. However, there are at least four common issues associated with the existing fusion methods. First, many existing fusion methods simply concatenate features from each modality without considering the correlations among different modalities. Second, most existing methods often make prediction based on a single classifier, which might not be able to address the heterogeneity of the Alzheimer's disease (AD) progression. Third, many existing methods often employ feature selection (or reduction) and classifier training in two independent steps, without considering the fact that the two pipelined steps are highly related to each other. Forth, there are missing neuroimaging data for some of the participants (e.g., missing PET data), due to the participants' "no-show" or dropout. In this paper, to address the above issues, we propose an early AD diagnosis framework via novel multi-modality latent space inducing ensemble SVM classifier. Specifically, we first project the neuroimaging data from different modalities into a latent space, and then map the learned latent representations into the label space to learn multiple diversified classifiers. Finally, we obtain the more reliable classification results by using an ensemble strategy. More importantly, we present a Complete Multi-modality Latent Space (CMLS) learning model for complete multi-modality data and also an Incomplete Multi-modality Latent Space (IMLS) learning model for incomplete multi-modality data. Extensive experiments using the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset have demonstrated that our proposed models outperform other state-of-the-art methods., (Copyright © 2019. Published by Elsevier B.V.)

The fusion of complementary information contained in multi-modality data [e.g., magnetic resonance imaging (MRI), positron emission tomography (PET), and genetic data] has advanced the progress of automated Alzheimer's disease (AD) diagnosis. However, multi-modality based AD diagnostic models are often hindered by the missing data, i.e., not all the subjects have complete multi-modality data. One simple solution used by many previous studies is to discard samples with missing modalities. However, this significantly reduces the number of training samples, thus leading to a sub-optimal classification model. Furthermore, when building the classification model, most existing methods simply concatenate features from different modalities into a single feature vector without considering their underlying associations. As features from different modalities are often closely related (e.g., MRI and PET features are extracted from the same brain region), utilizing their inter-modality associations may improve the robustness of the diagnostic model. To this end, we propose a novel latent representation learning method for multi-modality based AD diagnosis. Specifically, we use all the available samples (including samples with incomplete modality data) to learn a latent representation space. Within this space, we not only use samples with complete multi-modality data to learn a common latent representation, but also use samples with incomplete multi-modality data to learn independent modality-specific latent representations. We then project the latent representations to the label space for AD diagnosis. We perform experiments using 737 subjects from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database, and the experimental results verify the effectiveness of our proposed method.

Brain-wide and genome-wide association (BW-GWA) study is presented in this paper to identify the associations between the brain imaging phenotypes (i.e., regional volumetric measures) and the genetic variants [i.e., single nucleotide polymorphism (SNP)] in Alzheimer's disease (AD). The main challenges of this study include the data heterogeneity, complex phenotype-genotype associations, high-dimensional data (e.g., thousands of SNPs), and the existence of phenotype outliers. Previous BW-GWA studies, while addressing some of these challenges, did not consider the diagnostic label information in their formulations, thus limiting their clinical applicability. To address these issues, we present a novel joint projection and sparse regression model to discover the associations between the phenotypes and genotypes. Specifically, to alleviate the negative influence of data heterogeneity, we first map the genotypes into an intermediate imaging-phenotype-like space. Then, to better reveal the complex phenotype-genotype associations, we project both the mapped genotypes and the original imaging phenotypes into a diagnostic-label-guided joint feature space, where the intraclass projected points are constrained to be close to each other. In addition, we use l 2,1 -norm minimization on both the regression loss function and the transformation coefficient matrices, to reduce the effect of phenotype outliers and also to encourage sparse feature selections of both the genotypes and phenotypes. We evaluate our method using AD neuroimaging initiative dataset, and the results show that our proposed method outperforms several state-of-the-art methods in term of the average root-mean-square error of genome-to-phenotype predictions. Besides, the associated SNPs and brain regions identified in this study have also been shown in the previous AD-related studies, thus verifying the effectiveness and potential of our proposed method in AD pathogenesis study.

Effective utilization of heterogeneous multi-modal data for Alzheimer's Disease (AD) diagnosis and prognosis has always been hampered by incomplete data. One method to deal with this is low-rank matrix completion (LRMC), which simultaneous imputes missing data features and target values of interest. Although LRMC yields reasonable results, it implicitly weights features from all the modalities equally, ignoring the differences in discriminative power of features from different modalities. In this paper, we propose stability-weighted LRMC (swLRMC), an LRMC improvement that weights features and modalities according to their importance and reliability . We introduce a method, called stability weighting , to utilize subsampling techniques and outcomes from a range of hyper-parameters of sparse feature learning to obtain a stable set of weights. Incorporating these weights into LRMC, swLRMC can better account for differences in features and modalities for improving diagnosis. Experimental results confirm that the proposed method outperforms the conventional LRMC, feature-selection based LRMC, and other state-of-the-art methods.

Alzheimer's disease (AD) is an irreversible neurodegenerative disease and affects a large population in the world. Cognitive scores at multiple time points can be reliably used to evaluate the progression of the disease clinically. In recent studies, machine learning techniques have shown promising results on the prediction of AD clinical scores. However, there are multiple limitations in the current models such as linearity assumption and missing data exclusion. Here, we present a nonlinear supervised sparse regression-based random forest (RF) framework to predict a variety of longitudinal AD clinical scores. Furthermore, we propose a soft-split technique to assign probabilistic paths to a test sample in RF for more accurate predictions. In order to benefit from the longitudinal scores in the study, unlike the previous studies that often removed the subjects with missing scores, we first estimate those missing scores with our proposed soft-split sparse regression-based RF and then utilize those estimated longitudinal scores at all the previous time points to predict the scores at the next time point. The experiment results demonstrate that our proposed method is superior to the traditional RF and outperforms other state-of-art regression models. Our method can also be extended to be a general regression framework to predict other disease scores., Competing Interests: statement The authors have no conflicts of interest to disclose., (Copyright © 2016 Elsevier Inc. All rights reserved.)

Accurate classification of Alzheimer's disease (AD) and its prodromal stage, mild cognitive impairment (MCI), plays a critical role in possibly preventing progression of memory impairment and improving quality of life for AD patients. Among many research tasks, it is of a particular interest to identify noninvasive imaging biomarkers for AD diagnosis. In this paper, we present a robust deep learning system to identify different progression stages of AD patients based on MRI and PET scans. We utilized the dropout technique to improve classical deep learning by preventing its weight coadaptation, which is a typical cause of overfitting in deep learning. In addition, we incorporated stability selection, an adaptive learning factor, and a multitask learning strategy into the deep learning framework. We applied the proposed method to the ADNI dataset, and conducted experiments for AD and MCI conversion diagnosis. Experimental results showed that the dropout technique is very effective in AD diagnosis, improving the classification accuracies by 5.9% on average as compared to the classical deep learning methods.